Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease

Authors Decramer ML, Hanania NA, Lötvall JO, Yawn BP

Received 10 October 2012

Accepted for publication 26 November 2012

Published 25 January 2013 Volume 2013:8 Pages 53—64

DOI https://dx.doi.org/10.2147/COPD.S39018

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Marc L Decramer,1 Nicola A Hanania,2 Jan O Lötvall,3 Barbara P Yawn4

1Respiratory Division, University Hospital, KU Leuven, Belgium; 2Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA; 3Krefting Research Centre, University of Gothenburg, Gothenburg, Sweden; 4Department of Research, Olmsted Medical Center, Rochester, MN, USA

Background: Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting ß2-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths.
Methods: We searched PubMed for placebo-controlled studies evaluating long-term (≥24 weeks) use of formoterol, salmeterol, or indacaterol in patients with stable COPD, published between January 1990 and September 2012. We summarized data relating to exacerbations and adverse events, particularly events related to COPD.
Results: From 20 studies examined (8774 LABA-treated patients), there was no evidence of an association between LABA treatment and increased exacerbations, COPD-related adverse events, or deaths. Where analyzed as an efficacy outcome, LABA treatment was generally associated with significant or numerical reductions in COPD exacerbations compared with placebo. Incidences of COPD-related adverse events were similar for active and placebo treatments. The incidence of adverse events typically associated with the ß2-agonist drug class such as skeletal muscle tremors and palpitations was low (often <1% of patients), and there were no reports of increased incidence of cardiac arrhythmias. The systemic effects of ß2-adrenoceptor stimulation, such as high glucose and potassium levels, were considered minor.
Conclusion: Current evidence from clinical studies of the safety and tolerability profile of LABAs supports their long-term use in COPD.

Keywords: LABA, formoterol, salmeterol, indacaterol, bronchodilator, COPD

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Standardized evaluation of lung congestion during COPD exacerbation better identifies patients at risk of dying

Høiseth AD, Omland T, Karlsson BD, Brekke PH, Søyseth V

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:621-629

Published Date: 6 December 2013

SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe

Fležar M, Jahnz-Różyk K, Enache G, Martynenko T, Kristufek P, Škrinjarić-Cincar S, Kadlecová P, Martinovic G,

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:483-492

Published Date: 9 October 2013

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:425-432

Published Date: 18 September 2013

The 6-minute pegboard and ring test is correlated with upper extremity activity of daily living in chronic obstructive pulmonary disease

Takeda K, Kawasaki Y, Yoshida K, Nishida Y, Harada T, Yamaguchi K, Ito S, Hashimoto K, Matsumoto S, Yamasaki A, Igishi T, Shimizu E

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:347-351

Published Date: 23 July 2013

The association between COPD and heart failure risk: a review

de Miguel Díez J, Chancafe Morgan J, Jiménez García R

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:305-312

Published Date: 28 June 2013

Symptom variability in COPD: a narrative review

Lopez-Campos JL, Calero C, Quintana-Gallego E

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:231-238

Published Date: 7 May 2013

Assessing the role of cognitive behavioral therapy in the management of chronic nonspecific back pain

Sveinsdottir V, Eriksen HR, Reme SE

Journal of Pain Research 2012, 5:371-380

Published Date: 11 October 2012

Lung microbiology and exacerbations in COPD

Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:555-569

Published Date: 31 August 2012

Epidemiology of chronic obstructive pulmonary disease: a literature review

Rycroft CE, Heyes A, Lanza L, Becker K

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:457-494

Published Date: 20 July 2012

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011